GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » NonCurrent Deferred Liabilities

Labiana Health (XMAD:LAB) NonCurrent Deferred Liabilities : €0.00 Mil (As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Labiana Health's non-current deferred liabilities for the quarter that ended in Dec. 2022 was €0.00 Mil.

Labiana Health NonCurrent Deferred Liabilities Historical Data

The historical data trend for Labiana Health's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health NonCurrent Deferred Liabilities Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
NonCurrent Deferred Liabilities
- - -

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
NonCurrent Deferred Liabilities - - - -

Labiana Health NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Labiana Health's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.